Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study

被引:132
|
作者
Pearce, Lindsay A. [1 ]
Min, Jeong Eun [1 ]
Piske, Micah [1 ]
Zhou, Haoxuan [1 ]
Homayra, Fahmida [1 ]
Slaunwhite, Amanda [2 ]
Irvine, Mike [2 ]
McGowan, Gina [3 ]
Nosyk, Bohdan [1 ,4 ]
机构
[1] British Columbia Ctr Excellence HIV AIDS, Hlth Econ Res Unit, Vancouver, BC V6Z 1Y6, Canada
[2] British Columbia Ctr Dis Control & Prevent, Vancouver, BC V5Z 4R4, Canada
[3] British Columbia Minist Mental Hlth & Addict, Victoria, BC V8W 9P1, Canada
[4] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada
来源
BMJ-BRITISH MEDICAL JOURNAL | 2020年 / 368卷
关键词
PHARMACOLOGICAL-TREATMENT; METHADONE; DRUG; BUPRENORPHINE; DEPENDENCE; HEROIN; THERAPY;
D O I
10.1136/bmj.m772
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective - To compare the risk of mortality among people with opioid use disorder on and off opioid agonist treatment (OAT) in a setting with a high prevalence of illicitly manufactured fentanyl and other potent synthetic opioids in the illicit drug supply. Design - Population based retrospective cohort study. Setting - Individual level linkage of five health administrative datasets capturing drug dispensations, hospital admissions, physician billing records, ambulatory care reports, and deaths in British Columbia, Canada. Participants - 55 347 people with opioid use disorder who received OAT between 1 January 1996 and 30 September 2018. Main outcome measures - All cause and cause specific crude mortality rates (per 1000 person years) to determine absolute risk of mortality and all cause age and sex standardised mortality ratios to determine relative risk of mortality compared with the general population. Mortality risk was calculated according to treatment status (on OAT, off OAT), time since starting and stopping treatment (1, 2, 3-4, 5-12, >12 weeks), and medication type (methadone, buprenorphine/naloxone). Adjusted risk ratios compared the relative risk of mortality on and off OAT over time as fentanyl became more prevalent in the illicit drug supply. Results- 7030 (12.7%) of 55 347 OAT recipients died during follow-up. The all cause standardised mortality ratio was substantially lower on OAT (4.6, 95% confidence interval 4.4 to 4.8) than off OAT (9.7, 9.5 to 10.0). In a period of increasing prevalence of fentanyl, the relative risk of mortality off OAT was 2.1 (95% confidence interval 1.8 to 2.4) times higher than on OAT before the introduction of fentanyl, increasing to 3.4 (2.8 to 4.3) at the end of the study period (65% increase in relative risk). Conclusions - Retention on OAT is associated with substantial reductions in the risk of mortality for people with opioid use disorder. The protective effect of OAT on mortality increased as fentanyl and other synthetic opioids became common in the illicit drug supply, whereas the risk of mortality remained high off OAT. As fentanyl becomes more widespread globally, these findings highlight the importance of interventions that improve retention on opioid agonist treatment and prevent recipients from stopping treatment.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Concurrent prescriptions for opioids and benzodiazepines and risk of opioid overdose: protocol for a retrospective cohort study using linked administrative data
    Liu, Erin Y.
    Tamblyn, Robyn
    Filion, Kristian B.
    Buckeridge, David L.
    BMJ OPEN, 2021, 11 (02):
  • [22] Risk of Opioid Overdose Associated With Concomitant Use of Opioids and Skeletal Muscle Relaxants: A Population-Based Cohort Study
    Li, Yan
    Delcher, Chris
    Wei, Yu-Jung Jenny
    Reisfield, Gary M.
    Brown, Joshua D.
    Tighe, Patrick
    Winterstein, Almut G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (01) : 81 - 89
  • [23] Reductions in emergency department presentations associated with opioid agonist treatment vary by geographic location: A retrospective study in New South Wales, Australia
    Jones, Nicola R.
    Shanahan, Marian
    Dobbins, Timothy
    Degenhardt, Louisa
    Montebello, Mark
    Gisev, Natasa
    Larney, Sarah
    DRUG AND ALCOHOL REVIEW, 2019, 38 (06) : 690 - 698
  • [24] Population-Based Opioid Prescribing and Overdose Deaths in the USA: an Observational Study
    Olfson, Mark
    Waidmann, Timothy
    King, Marissa
    Pancini, Vincent
    Schoenbaum, Michael
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2023, 38 (02) : 390 - 398
  • [25] Mortality and causes of death among patients with opioid use disorder receiving opioid agonist treatment: a national register study
    Anne Berit Bech
    Thomas Clausen
    Helge Waal
    Jūratė Šaltytė Benth
    Ivar Skeie
    BMC Health Services Research, 19
  • [26] Mortality and causes of death among patients with opioid use disorder receiving opioid agonist treatment: a national register study
    Bech, Anne Berit
    Clausen, Thomas
    Waal, Helge
    Benth, Jurate Saltyte
    Skeie, Ivar
    BMC HEALTH SERVICES RESEARCH, 2019, 19 (1)
  • [27] Gender differences in physical morbidity in opioid agonist treatment patients: population-based cohort studies from the Czech Republic and Norway
    Rolova, Gabriela
    Eide, Desiree
    Gabrhelik, Roman
    Odsbu, Ingvild
    Clausen, Thomas
    Skurtveit, Svetlana
    SUBSTANCE ABUSE TREATMENT PREVENTION AND POLICY, 2023, 18 (01)
  • [28] Impact of opioid abuse on oral health: a retrospective cohort study
    Smeda, Martyna
    Knogl, Constanze
    Mueller, Karolina
    Stahl, Martin
    Buchalla, Wolfgang
    Keim, Lukas
    Piendl, Ursula
    Wodarz, Norbert
    Widbiller, Matthias
    FRONTIERS IN ORAL HEALTH, 2025, 6
  • [29] Association Between Receipt of Antidepressants and Retention in Buprenorphine Treatment for Opioid Use Disorder: A Population-Based Retrospective Cohort Study
    Zhang, Kun
    Jones, Christopher M.
    Compton, Wilson M.
    Guy, Gery P.
    Evans, Mary E.
    Volkow, Nora D.
    JOURNAL OF CLINICAL PSYCHIATRY, 2022, 83 (03)
  • [30] Comparative Safety Analysis of Opioid Agonist Treatment in Pregnant Women with Opioid Use Disorder: A Population-Based Study
    Wang, Shuang
    Meador, Kimford J.
    Pawasauskas, Jayne
    Lewkowitz, Adam K.
    Ward, Kristina E.
    Brothers, Todd N.
    Hartzema, Abraham
    Quilliam, Brian J.
    Wen, Xuerong
    DRUG SAFETY, 2023, 46 (03) : 257 - 271